Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

Liana K. Billings, Stanley H. Hsia, Harold Bays, Beth Tidemann‐Miller, Jessica O’Hagan, Lai Tham, Annabelle Butler, Christof Kazda, Kieren J. Mather, Tamer Coşkun